6 Hartford Business Journal • May 25, 2020 • www.HartfordBusiness.com
Though our Neuroinnovation portfolio, we are
developing therapies across three platforms:
calcitonin gene-related peptide (CGRP)
receptor antagonism for migraine; glutamate
modulation for neurologic and neuropsychiatric
disorders; and myeloperoxidase (MPO)
inhibition for neuroinflammation.
© 2020 Biohaven Pharmaceuticals. All rights reserved.
Biohaven is a patient-first company.
We push the boundaries of science to develop innovative
medicines for neurological diseases that are often chronic,
incurable and represent an enormous burden to patients,
families and society.
